GET THE APP

Formulation of liposomes for oral delivery of phyllanthin and hyp | 49080

Oncology & Cancer Case Reports

ISSN - 2471-8556

Formulation of liposomes for oral delivery of phyllanthin and hypophyllanthin

15th World Congress on CANCER THERAPY, BIOMARKERS & CLINICAL RESEARCH

December 05-07, 2016 Philadelphia, USA

Thahera Parveen Dandu and Madhukiran Parvathaneni

Oman Pharmaceutical Products (Gulf), Oman
Harrisburg University of Science & Technology, USA

Scientific Tracks Abstracts: Oncol Cancer Case Rep

Abstract :

Formulation of liposomes in order to enhance the oral bioavailability of phyllanthin and hypophyllanthin with proven anticancer activity. The bioactive lignans, Phyllanthin and hypophyllanthin are formulated in to conventional and PEGylated liposomes using different ratios of DSPC, DSPE-MPEG2000 and cholesterol by film hydration technique. Evaluation of the prepared liposomes was done by the determination of encapsulation efficiencies, particle size analysis, polydispersity index (PDI), zeta potential, TEM analysis, IR studies, DSC studies and powder X-RD analysis. The drug retention in vitro and pharmacokinetic properties in vivo are investigated. A new, simple and sensitive analytical method using HPLC with photodiode array (PDA) detection was developed for the determination of phyllanthin and hypophyllanthin in solvent system and in plasma.Conventional and pegylated liposomes are successfully formulated using film hydration technique with encapsulation efficiencies of 86.47%?±0.13% and 83.68?±0.22% (phyllanthin), 84.83?±0.19% and 81.87?±0.54% (hypophyllanthin). The HPLC method was successfully applied for quantification of lignans with recorded LOD and LOQ values of 56.15 ng/mL & 169.99 ng/mL (phyllanthin) and 56.04 ng/mL and 169.82 ng/mL (hypophyllanthin), respectively. From the in vivo pharmacokinetic studies, it was observed that the oral bioavailability of lignans was enhanced as indicated by AUC values of 5265.30?±275.52 ng.h/mL (phyllanthin), 15217.60?±987.96 ng.h/mL (conventional liposomal phyllanthin), 30810.23?±2587.96 ng.h/mL (pegylated liposomal phyllanthin) and 7354.42?±578.2 ng.h/mL (hypophyllanthin), 29222.4?±1951.8 ng.h/mL (conventional liposomal hypophyllanthin), 58631.87?±2515.46 ng.h/mL (pegylated liposomal hypophyllanthin). The developed liposomal formulations of both the lignans, showed extended drug release over 24 h in in vitro drug release studies. Pharmacokinetic studies showed the enhancement of oral bioavailability by several folds for liposomes. The enhanced oral bioavailability of lignan loaded liposomes will be helpful for the production of desired pharmacological activity relatively at a lower dose when compared to their respective free drugs.

Biography :

ThaheraParveenDandu has completed her PhD at the age of 35 years from Andhra University. She is working as Deputy Manager, Formulation R&D atOman Pharmaceutical Products, Gulf based pharmaceutical company. She has published more than 9 papers in reputed journals.

Madhukiran Parvathaneni has completed his PhD at the age of 26 years from NAIP/ICAR Project, Andhra University. He is working as Senior Regulatory Associate with a global pharmaceutical CRO company. He has published more than 14 papers in reputed journals and serving as an editorial board member and reviewerfor more than 10 PubMed, Springer and Elsevier Journals.

Email: tahera23in@gmail.com

Top @@PDUjn